A multi-national, multi-center, DB [double-blind], placebo-controlled, parallel group, fixed dose efficacy and safety study of SR58611A [amibegron] 350 mg twice daily vs. placebo in adults with major depressive disorder on concomitant treatment with escitalopram 10mg/d.

Trial Profile

A multi-national, multi-center, DB [double-blind], placebo-controlled, parallel group, fixed dose efficacy and safety study of SR58611A [amibegron] 350 mg twice daily vs. placebo in adults with major depressive disorder on concomitant treatment with escitalopram 10mg/d.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Amibegron (Primary) ; Escitalopram
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms ALBERIO
  • Most Recent Events

    • 02 Dec 2008 Actual patient number (510) added as reported by ClinicalTrials.gov.
    • 02 Dec 2008 Actual start date changed from Feb 2007 to Jan 2007 as reported by ClinicalTrials.gov.
    • 02 Dec 2008 Additional trial identifier EudraCT2006-004146-16 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top